カテゴリ： GlobalData, アメリカ, 企業調査

Global Blood Therapeutics Inc (GBT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Global Blood Therapeutics Inc (GBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8250
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company’s lead drug candidate GBT440 is an oral, small molecule drug for the treatment of sickle cell disease. Its GBT440 is a hemoglobin modifier which targets the mechanism of red blood cell sickling for the treatment of SCD. GBT’s pipeline also includes an oral kallikrein inhibitor to prevent hereditary angioedema attacks. The company also develops therapies which are in preclinical and preliminary clinical stage for the treatment of for acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms of blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Global Blood Therapeutics Inc (GBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Global Blood Therapeutics Raises USD48 Million in Series B Financing 11
Global Blood Therapeutics Raises US$50 Million In Series A Financing 13
Partnerships 14
HitGen Enters into Research Agreement with Global Blood Therapeutics 14
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15
Licensing Agreements 16
Global Blood Therapeutics Enters into Licensing Agreement with Roche 16
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18
Equity Offering 19
Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19
Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21
Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23
Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25
Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27
Global Blood Therapeutics Raises Funds through Private Placement of Shares 29
Acquisition 30
Novo Nordisk May Acquire Global Blood Therapeutics 30
Global Blood Therapeutics Inc – Key Competitors 31
Global Blood Therapeutics Inc – Key Employees 32
Global Blood Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
Aug 02, 2018: Global Blood Therapeutics reports second quarter 2018 financial results 34
May 07, 2018: Global Blood Therapeutics Announces First Quarter 2018 Financial Results 36
Feb 27, 2018: GBT Reports Fourth Quarter and Year-End 2017 Financial Results 37
Nov 02, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results 38
Aug 07, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results 40
May 01, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results 42
Mar 13, 2017: Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results 43
Corporate Communications 45
Dec 22, 2017: GBT Appoints Wendy L. Yarno to Board of Directors 45
Product News 46
10/24/2017: Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 46
10/11/2017: Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype 47
10/03/2017: Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October 49
02/14/2017: Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters 50
Product Approvals 51
Sep 05, 2017: Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease 51
Jun 28, 2017: Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) 52
Clinical Trials 53
Oct 23, 2017: Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program 53
Jul 10, 2017: Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population 54
Jun 23, 2017: Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease 55
May 18, 2017: Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress 56
Feb 16, 2017: Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions 57
Jan 18, 2017: Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Global Blood Therapeutics Raises USD48 Million in Series B Financing 11
Global Blood Therapeutics Raises US$50 Million In Series A Financing 13
HitGen Enters into Research Agreement with Global Blood Therapeutics 14
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15
Global Blood Therapeutics Enters into Licensing Agreement with Roche 16
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18
Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19
Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21
Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23
Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25
Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27
Global Blood Therapeutics Raises Funds through Private Placement of Shares 29
Novo Nordisk May Acquire Global Blood Therapeutics 30
Global Blood Therapeutics Inc, Key Competitors 31
Global Blood Therapeutics Inc, Key Employees 32

List of Figures
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Global Blood Therapeutics Inc (GBT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Innovation Pharmaceuticals Inc (IPIX)-医療機器分野：企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company pipeline products include kevetrin for the …
  • Advanced Emissions Solutions, Inc. (ADES)：企業の財務・戦略的SWOT分析
    Advanced Emissions Solutions, Inc. (ADES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Stabilis Solutions Inc (AETI)：企業の財務・戦略的SWOT分析
    Summary Stabilis Solutions Inc (Stabilis Solutions) formerly, Stabilis Energy Inc a subsidiary of Amnor Technologies Inc, is a provider of power delivery solutions. The company's products comprise power distribution and power conversion products. Stabilis Solutions power distribution products compri …
  • Zagro Asia Ltd：企業の戦略的SWOT分析
    Zagro Asia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • NMDC Ltd：企業のM&A・事業提携・投資動向
    NMDC Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NMDC Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Engro Corp Ltd (ENGRO)：企業の財務・戦略的SWOT分析
    Engro Corp Ltd (ENGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Royal BAM Group nv：戦略・SWOT・企業財務分析
    Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report Summary Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GeneNews Ltd (GEN)：医療機器：M&Aディール及び事業提携情報
    Summary GeneNews Ltd (GeneNews) is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNew …
  • Oman Oil Co SAOC：石油・ガス：M&Aディール及び事業提携情報
    Summary Oman Oil Company SAOC (Oman Oil Company) is an oil and gas service provider that offers investment facilities for the growth and development of energy sector. The association invests and develops the areas of production, exploration, and related services, energy infrastructure and shipping, …
  • Ball Aerospace & Technologies Corp.：企業の戦略・SWOT・財務情報
    Ball Aerospace & Technologies Corp. - Strategy, SWOT and Corporate Finance Report Summary Ball Aerospace & Technologies Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Alvogen Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Alvogen Inc (Alvogen) is a pharmaceutical company that develops, manufactures and markets generic pharmaceuticals, brand and over the counter (OTC) products. The company offers generic medications in the therapeutic areas of oncology, cardiology, respiratory, neurology and gastroenterology. …
  • OraSure Technologies Inc (OSUR)：医療機器：M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • Royal Mail plc：企業の戦略・SWOT・財務情報
    Royal Mail plc - Strategy, SWOT and Corporate Finance Report Summary Royal Mail plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • InVitae Corp (NVTA)：医療機器：M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • Tereos：企業の戦略・SWOT・財務情報
    Tereos - Strategy, SWOT and Corporate Finance Report Summary Tereos - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Novita Healthcare Ltd (NHL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Novita Healthcare Ltd (Novita Healthcare), formerly Avexa Ltd is a medical technology company that focuses on the measurement and treatment of attention difficulties in early childhood. The company operates through its subsidiary The Tali technology, which is developing a tablet based softwa …
  • QuadraMed Corp：医療機器：M&Aディール及び事業提携情報
    Summary Quadramed Corporation (Quadramed), is a N. Harris Computer Corp., is a healthcare technologies and service provider. It provides solutions to various healthcare organizations to improve the safety, efficiency and quality of patient care. The company's solutions enable its clients in streamli …
  • Torax Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary TORAX Medical Inc (Torax Medical), a subsidiary of Ethicon US LLC, is a healthcare company that offers technology solutions. The company offers LINX reflux management system, a clinical stage medical device. Torax Medical offers treatment for gastro esophageal reflux disease that can turn in …
  • Getlink SE (GET)：企業の財務・戦略的SWOT分析
    Getlink SE (GET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kangwon Land Inc.：企業の戦略・SWOT・財務情報
    Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report Summary Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆